These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 31822200)

  • 1. Impact of transitioning inpatient chemotherapy regimens to the outpatient setting.
    Corsi MP; Shea K; W Knoebel R
    J Oncol Pharm Pract; 2020 Sep; 26(6):1324-1330. PubMed ID: 31822200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Cost Comparison Evaluation of Inpatient Versus Outpatient Administration of EPOCH-Containing Regimens in Non-Hodgkin Lymphoma.
    Evans SS; Gandhi AS; Clemmons AB; DeRemer DL
    J Pharm Pract; 2017 Aug; 30(4):400-405. PubMed ID: 27432462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Making moves: Transitioning R-EPOCH to the ambulatory setting.
    Martin AL; Frank JP; Waggoner ML
    J Oncol Pharm Pract; 2018 Dec; 24(8):617-622. PubMed ID: 28782408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of a pharmacy-managed program for the transition of chemotherapy to the outpatient setting.
    McBride A; Campen CJ; Camamo J; Maloney M; Persky D; Kurtin SE; Barket NL; Krishnadasan R; Elquza E; Anwer F; Weibel K
    Am J Health Syst Pharm; 2018 May; 75(9):e246-e258. PubMed ID: 29691269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing Hospitalizations: Institution of Outpatient Infusional EPOCH-Based Chemotherapy at a Safety Net Hospital.
    Keshvani N; Hon M; Gupta A; Brown TJ; Roy L; Marley E; Lindsey S; Johnson DH; Sadeghi N; Li HC
    J Oncol Pract; 2019 Aug; 15(8):e644-e651. PubMed ID: 31206340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and financial analysis of outpatient dose-adjusted EPOCH for B-cell lymphoma at a tertiary comprehensive cancer center.
    Li W; Richter KA; Tobon KA; McCarthy KT; Kubal TE
    J Oncol Pharm Pract; 2021 Oct; 27(7):1684-1690. PubMed ID: 33092499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.
    David RJ; Baran A; Loh KP; Casulo C; Barr PM; Friedberg JW; Reagan PM
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):781-787. PubMed ID: 30262330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.
    Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
    Ann Oncol; 2003; 14 Suppl 1():i11-6. PubMed ID: 12736225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile.
    Banh C; Valsvik K; Arredondo A; Notbohm K; Elquza E; Babiker H; Kraft A; Boiles AR; Persky D; Ortega A; McBride A
    Support Care Cancer; 2022 Mar; 30(3):2755-2766. PubMed ID: 34825982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma.
    Wilder DD; Ogden JL; Jain VK
    Clin Lymphoma; 2001 Mar; 1(4):285-92. PubMed ID: 11707843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastomeric pump supporting transition of the EPOCH regimen to outpatient care.
    Svirskis D; Behera S; Naidoo N; Beachman J; Raina T; Zhou Y; Berkahn L; Costello I; Gu Y
    J Oncol Pharm Pract; 2019 Jun; 25(4):831-840. PubMed ID: 29540104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.
    Vaughn JE; Othus M; Powell MA; Gardner KM; Rizzuto DL; Hendrie PC; Becker PS; Pottinger PS; Estey EH; Walter RB
    JAMA Oncol; 2015 Nov; 1(8):1120-7. PubMed ID: 26355382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inpatient versus outpatient vincristine, dactinomycin, and cyclophosphamide for pediatric cancers: Quality and cost implications.
    Beaty RS; Bernhardt MB; Berger AH; Hesselgrave JE; Russell HV; Okcu MF
    Pediatr Blood Cancer; 2015 Nov; 62(11):1925-8. PubMed ID: 26152314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
    Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
    Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].
    Kataoka T; Sakurashita H; Taogoshi T; Nishigakiuchi R; Murase T; Izumitani S; Saeki Y; Matsuo H
    Yakugaku Zasshi; 2019; 139(4):629-633. PubMed ID: 30930398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma.
    Vose J; Sneller V
    Ann Oncol; 2003; 14 Suppl 1():i17-20. PubMed ID: 12736226
    [No Abstract]   [Full Text] [Related]  

  • 18. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
    Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma.
    Lamar ZS; Fino N; Palmer J; Gruber L; Morris BB; Raetskaya-Solntseva O; Kennedy L; Vaidya R; Hurd D; Zamkoff K
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):76-81. PubMed ID: 26725264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
    Giulino-Roth L; O'Donohue T; Chen Z; Bartlett NL; LaCasce A; Martin-Doyle W; Barth MJ; Davies K; Blum KA; Christian B; Casulo C; Smith SM; Godfrey J; Termuhlen A; Oberley MJ; Alexander S; Weitzman S; Appel B; Mizukawa B; Svoboda J; Afify Z; Pauly M; Dave H; Gardner R; Stephens DM; Zeitler WA; Forlenza C; Levine J; Williams ME; Sima JL; Bollard CM; Leonard JP
    Br J Haematol; 2017 Dec; 179(5):739-747. PubMed ID: 29082519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.